- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of recurrent clostridium difficile infection (CDI)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Bezlotoxumab – March 2020
Bezlotoxumab: Solution concentrate for I.V. infusion 1000 mg in 40 ml; Zinplava®
Last updated
3 July 2020